mapping the effectiveness and risks of glp-1 receptor agonists pdf Combined associations a healthy lifestyle with cardiovascular outcomes among individuals with type 2 diabetes: a prospective cohort study Comparative effectiveness of GLP-1 receptor
Description
Transl Behav Med
sodium-glucose cotransporter 2 inhibitors (SGLT2) in people with type 2 diabetes The 5-year survival probability for those with obesity and breast cancer using a GLP-1 was 97.4%, with the 10-year survival being 96%
EMPA-REG OUTCOME (Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients) was the first major trial published evaluating SGLT2-i use for reduction of MACE in patients with type 2 diabetes and known CVD on empagliflozin
Understanding weight regain after a nutritional weight loss intervention: systematic review and meta-analysis
Komaroff, MD, Editor in Chief, Harvard Health Letter
Systemic lupus erythematosus Lupus is one of the more complex autoimmune conditions, involving multiple organ systems and antibody-mediated damage
